Better design of rodent trials could reduce the cost and time required for cancer drug development, according to a commentary in the October 28 online issue of the Journal of the National Cancer ...
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must ... . Four days after they exposed the cells to the new drug-delivery system, 59.5 percent of ...
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any ...
... Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest ... analyse tumour tissue for individual patient drug responses on the molecular level. To date most tests ...
... potential to serve as the basis for anti-cancer drug development.
Fuchs and colleagues are continuing to refine ... a nearly 100-fold difference in toxicity to cancer cells vs. healthy cells, meaning it ...
... . The Bcl-2 protein has long been implicated in protecting cancer cells from apoptosis (programmed cell death), the ... for Bcl-2-based drug leads and cancer drug development," said Xiao-kun Zhang, Ph.D ...
... group from Boston; a step that, if it pans out, could impact a wide swath of cancer drug development. The research is still in its early stages - mouse models - but the potential implications led to ...
... ASCO), an allowance for updating previously presented data, and the more specialised anti-cancer drug development focus of the ENA symposia. There remains room for improvement in both conferences for ...
... tumors
Prof. Zilberman says that her biodegradable drug-eluting fibers –– only five times the thickness ... conducted biological experiments using an anti-cancer drug developed at TAU by Prof. Yoel Kloog ...
